AimThe current research aims to systematically review the rates of adherence reported in randomised controlled clinical trials of acamprosate. It also sought to determine the reliability of the adherence monitoring and measurement methods used in these trials.MethodsThe protocol for this review was pre-registered (PROSPERO: CRD42021230011). A search of the literature was conducted using OVID MEDLINE, Embase and PsycINFO from database inception to January 2021. Randomised controlled trials with a minimum sample size of 10 per treatment arm that compared the efficacy of acamprosate with placebo or other active medication in adults with a diagnosis of alcohol dependence were included. Data on rates of adherence, methods of measurement and moni...
Acamprosate is an FDA-approved medication that enhances abstinence in alcohol-dependent patients. A ...
Aims: This review assessed the published data on the cost-effectiveness of acamprosate for the treat...
Background Adherence to chronic therapy is a key determinant of patient health outcomes in chronic d...
This research was funded by Investigator Sponsored Trial (ISTBAL26102012) provided by Merck Serono L...
Objectives: We tested the hypothesis that poor adherence is associated with a greater risk of alcoho...
ARES is the first naturalistic study to assess the effect of a pharmacological agent in alcoholism: ...
general study on compliance conditions throughout a meta-analysis of 4354 patients treated with acam...
Method: Randomized parallel groups prospective trial to assess the efficacy of nursing follow up of...
The burden of chronic daily subcutaneous administration of pegvisomant on adherence has not been pre...
Background: The aim of this study is to assess the influence of early and late compliance of acampro...
International audienceBACKGROUND: International recommendations such as the CONSORT and Internationa...
BackgroundAcamprosate is an effective and cost-effective medication for alcohol relapse prevention b...
We compared effects of the standard 2 g dose (n=258) and an exploratory 3 g dose of acamprosate (n=8...
Background:; In pharmacotherapy, the achievement of a target clinical outcome requires a certain lev...
advance access publication 6 June 2005) Abstract — Aims: This review assessed the published data on ...
Acamprosate is an FDA-approved medication that enhances abstinence in alcohol-dependent patients. A ...
Aims: This review assessed the published data on the cost-effectiveness of acamprosate for the treat...
Background Adherence to chronic therapy is a key determinant of patient health outcomes in chronic d...
This research was funded by Investigator Sponsored Trial (ISTBAL26102012) provided by Merck Serono L...
Objectives: We tested the hypothesis that poor adherence is associated with a greater risk of alcoho...
ARES is the first naturalistic study to assess the effect of a pharmacological agent in alcoholism: ...
general study on compliance conditions throughout a meta-analysis of 4354 patients treated with acam...
Method: Randomized parallel groups prospective trial to assess the efficacy of nursing follow up of...
The burden of chronic daily subcutaneous administration of pegvisomant on adherence has not been pre...
Background: The aim of this study is to assess the influence of early and late compliance of acampro...
International audienceBACKGROUND: International recommendations such as the CONSORT and Internationa...
BackgroundAcamprosate is an effective and cost-effective medication for alcohol relapse prevention b...
We compared effects of the standard 2 g dose (n=258) and an exploratory 3 g dose of acamprosate (n=8...
Background:; In pharmacotherapy, the achievement of a target clinical outcome requires a certain lev...
advance access publication 6 June 2005) Abstract — Aims: This review assessed the published data on ...
Acamprosate is an FDA-approved medication that enhances abstinence in alcohol-dependent patients. A ...
Aims: This review assessed the published data on the cost-effectiveness of acamprosate for the treat...
Background Adherence to chronic therapy is a key determinant of patient health outcomes in chronic d...